GNCA GENOCEA BIOSCIENCES

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Genocea Biosciences, Inc. Investors (GNCA)

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Genocea Biosciences, Inc. (“Genocea” or the “Company”) (NASDAQ: GNCA) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Genocea investigation page on our website at www.glancylaw.com/case/genocea-biosciences-inc.

On September 25, 2017, Genocea disclosed that it was ceasing spending and other activities related to GEN-003, and exploring “strategic alternatives.” Genocea also announced that it was cutting its workforce by 40%.

On this news, Genocea’s share price fell $4.08, or 76.5%, to close at $1.25 on September 26, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased Genocea securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
28/11/2017

Underlying

GNCAGENOCEA BIOSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GENOCEA BIOSCIENCES

 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

Genocea Announces Wind Down of Operations and Delisting From NASDAQ CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the ...

May 24, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Initiates Restructuring and Announces Plan to Explore Strategi...

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company,...

April 28, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Biosciences to Host Investor Webinar

Genocea Biosciences to Host Investor Webinar CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss , including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripher...

April 4, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conferenc...

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at . A replay of t...

March 14, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Provides Fourth Quarter 2021 Corporate Update

Genocea Provides Fourth Quarter 2021 Corporate Update Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy ca...

March 10, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch